This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.
­

About Nadine Baker

This author has not yet filled in any details.
So far Nadine Baker has created 31 blog entries.

New Permissible Ingredients Determination (No. 4) of 2019

The Permissible Ingredient Determination (No. 4 of 2019) has been published on the Federal Register of Legislation and commences 1st January 2020. It replaces the Therapeutic Goods (Permissible Ingredients) Determination ( No.3) 2019.

Key changes to note include;

Products containing Andrographis

Andrographis paniculata has […]

December 11th, 2019|Complementary Medicines, Listed Medicines, Regulation, TGA|

FSANZ Role in Food Regulation

Are you clear on what FSANZ’s role is in food regulation?

If not take 2 minutes to view this simple explanation

December 18th, 2018|Foods, FSANZ|

eBS Permitted Indications

Effective March 8th 2018 Permitted indications are now available through eBS for listed medicines.

The TGA has implemented a list of permitted indications for medicines listed under Section 26A of the Therapeutic Goods Act 1989 (the Act).

The list of permitted indications […]

March 13th, 2018|Complementary Medicines, Listed Medicines, Regulation, TGA|

TGA eBS Outage

The Therapeutic Goods Amendment Bill No.1. of 2017 received royal ascent on Monday 5th March, as such the proposed reforms have now begun to be implemented.

As of midday yesterday (6th March 2018), the TGA have temporarily closed the application section […]

Changes to the Uniform Recall Procedure for Therapeutic Goods

The Uniform Recall Procedure for Therapeutic Goods (URPTG) is a guidance document, which provides a standardised systematic procedure, to assist sponsors to conduct both recall and non-recall actions of therapeutic goods which are supplied, imported into or exported from Australia.

The […]

Consultation: Business Process Improvements Supporting Complementary Medicines Assessment Pathways

The TGA is seeking comments from interested parties on a range of reforms to the regulatory framework for complementary medicines, to address Government-agreed recommendations arising from the Review of Medicines and Medical Devices Regulation.

The consultation discusses:

A risk-based approach to […]

Updated Permissible Ingredients Determination

An updated version of the Therapeutic Goods (Permissible Ingredients) Determination was registered on the Federal Register of Legislation (FRL) in September 2017. The updated determination is titled the Therapeutic Goods (Permissible Ingredients) Determination No. 4 of 2017.

A total of 287 […]

October 13th, 2017|Complementary Medicines, Listed Medicines, Regulation, TGA|

Pharmacovigilance Update

On 1st September 2017, the TGA published the revised edition (Version 2.0) of the ‘Pharmacovigilance responsibilities of medicine sponsors – Australian recommendations and requirements’.  This guidance sets out the pharmacovigilance responsibilities of sponsors of medicines included on the Australian Register […]

September 26th, 2017|Complementary Medicines, Listed Medicines, Regulation, TGA|

Listed Medicine Reforms – Permitted Indications and Application Fees

Permitted Indications

The closing date for proposing additional indications or evidence qualifiers to the TGA to be considered for the core list of permitted indications, is 31 October 2017. After this date, the list will be finalised and if sponsors […]

September 26th, 2017|Complementary Medicines, Listed Medicines, Regulation, TGA|

Third Assessment Pathway for Listed Complementary Medicines

Intermediate Level – Listed Assessed Medicines

Reform recommendations for complementary medicines has seen the development of a three-tiered, risk-based framework for the regulation of CAM’s. The revised framework introduces a new (intermediate risk) assessment pathway sitting between the existing listed medicine […]

September 26th, 2017|Complementary Medicines, Listed Medicines, Regulation, TGA|